Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,681.12
(
-0.52%
)
US TECH 100
24,037.60
(
-0.39%
)
Dow Jones
46,600.70
(
-0.84%
)
Brent Oil
105.45
(
4.77%
)
Bitcoin
71,254.96
(
-3.64%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 59650

Monday, 04/21/2008 8:30:38 PM

Monday, April 21, 2008 8:30:38 PM

Post# of 257253
ALO – Here’s an excuse I haven’t seen before for withdrawing an NDA. The company says “certain issues” prevented the FDA from evaluating the NDA within the six-month window allotted for Priority Review and hence ALO will resubmit the NDA later.

http://biz.yahoo.com/iw/080421/0388936.html

Embeda is a formulation of morphine that contains embedded naltrexone. If a user crushes the capsule, the naltrexone is released and it supposedly averts a morphine-induced high, serving as a deterrent to abuse.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now